Loading...
•
Dec 31, 2022
Emergent BioSolutions Q4 2022 Earnings Report
Emergent BioSolutions reported a net loss of $88 million and total revenues of $331 million.
Key Takeaways
Emergent BioSolutions reported Q4 2022 financial results, with total revenues of $331 million and a net loss of $88 million. The company's performance reflects a period of transition, with a focus on public health preparedness and a strategy for sustainable long-term growth and profitability.
Total revenues for Q4 2022 were reported at $331 million, while FY 2022 revenues reached $1,121 million.
The company experienced a net loss of $88 million in Q4 2022, and $224 million for the full year 2022.
Adjusted EBITDA for Q4 2022 was $34 million, and $26 million for FY 2022.
The adjusted gross margin for Q4 2022 was 48%.
Emergent BioSolutions
Emergent BioSolutions
Emergent BioSolutions Revenue by Segment
Revenue by Segment
Anthrax MCM Revenue
CapyFin.comOther Products Revenue
CapyFin.comContracts and Grants Revenue
CapyFin.com Forward Guidance
For FY 2023, Emergent BioSolutions expects revenues between $1.1 billion and $1.2 billion, adjusted EBITDA between $75 million and $125 million, and an adjusted gross margin between 41% and 44%.
Positive Outlook
- Approval for over-the-counter NARCAN Nasal Spray.
- Launch of over-the-counter NARCAN Nasal Spray by the end of the summer 2023.
- Continued strong demand in the U.S. public interest (PIP) channel and Canada.
- Continued procurement and delivery of anthrax, smallpox and other related medical countermeasures (MCM) products to the U.S. and allied governments.
Challenges Ahead
- Potential impact of the sale of the travel health business to Bavarian Nordic is excluded.
- Continued re-baselining of the CDMO services business overall.
- Impact of reduced production output from the Camden facility.
Revenue & Expenses
Visualization of income flow from segment revenue to net income